<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6221">
  <stage>Registered</stage>
  <submitdate>3/10/2016</submitdate>
  <approvaldate>3/10/2016</approvaldate>
  <nctid>NCT02931838</nctid>
  <trial_identification>
    <studytitle>Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis</studytitle>
    <scientifictitle>A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>IM011-011</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Psoriasis</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BMS-986165
Treatment: drugs - Placebo for BMS-986165

Experimental: BMS-986165 Dose 1 - Specified dose of BMS-986165 on specified days.

Experimental: BMS-986165 Dose 2 - Specified dose of BMS-986165 on specified days.

Experimental: BMS-986165 Dose 3 - Specified dose of BMS-986165 on specified days.

Experimental: BMS-986165 Dose 4 - Specified dose of BMS-986165 on specified days.

Experimental: BMS-986165 Dose 5 - Specified dose of BMS-986165 on specified days.

Placebo Comparator: Placebo - Specified dose of Placebo for BMS-986165 on specified days.


Treatment: drugs: BMS-986165


Treatment: drugs: Placebo for BMS-986165


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of subjects reaching a 75% reduction in Psoriasis Area and Severity Index (PASI-75)</outcome>
      <timepoint>Day 1 to Day 85</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of adverse events (AEs)</outcome>
      <timepoint>Day 1 to 115</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects at week 12 with PASI-50</outcome>
      <timepoint>Baseline to Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects at week 12 with PASI-75</outcome>
      <timepoint>Baseline to Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects at week 12 with PASI-90</outcome>
      <timepoint>Baseline to Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects at week 12 with PASI-100</outcome>
      <timepoint>Baseline to Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>static Physician Global Assessment score (sPGA)</outcome>
      <timepoint>Day 1 to Day 85</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Dermatology Life Quality Index score (DLQI)</outcome>
      <timepoint>Day 1 to Day 85</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Trough observed plasma concentration of BMS-986165 (Ctrough)</outcome>
      <timepoint>Day 1 to Day 85</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        

          -  Male and female, ages 18 to 70 years

          -  Diagnosis of plaque psoriasis for 6 months

          -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy
             test, must not be pregnant, lactating, breastfeeding or planning pregnancy

          -  Males who are sexually active with WOCBP must agree to follow instructions for
             method(s) of contraception for the duration of treatment plus 5 half-lives of the
             study drug plus 90 days.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Any significant acute or chronic medical illness

          -  Blood transfusion within 4 weeks of study drug administration

          -  Inability to tolerate oral medication

          -  Positive hepatitis-B (HBV) surface antigen

          -  Positive hepatitis-C (HCV) antibody

          -  Any history or risk for tuberculosis (TB)

          -  Any major illness/condition or evidence of an unstable clinical condition

          -  Chest X-ray findings suspicious of infection at screening

          -  has received ustekinumab, secukinumab or ixekizumab within 6 months of first
             administration of study medication

          -  Has received anti-Tumor Necrosis Factor (TNF) inhibitor(s) within 2 months of first
             administration of study medication

          -  Has received Rituximab within 6 months of first administration of study medication

          -  Topical medications/treatments for psoriasis within 2 weeks of the first
             administration of any study medication

          -  Any systemic medications/treatments for psoriasis within 4 weeks of the first
             administration of any study medication

        Other protocol defined inclusion/exclusion criteria could apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>15/11/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>250</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>21/11/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC,WA</recruitmentstate>
    <hospital>Local Institution - Kogarah</hospital>
    <hospital>Local Institution - Sydney</hospital>
    <hospital>Local Institution - Wolloongabba</hospital>
    <hospital>Local Institution - Melbourne</hospital>
    <hospital>Local Institution - Nedlands</hospital>
    <postcode>2217 - Kogarah</postcode>
    <postcode>2065 - Sydney</postcode>
    <postcode>4151 - Wolloongabba</postcode>
    <postcode>3053 - Melbourne</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt/Main</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Gera</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kiel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Luebeck</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mahlow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Muenster</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Schwerin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Stuttgart</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Aichi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Fukuoka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hokkaido</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hyogo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Iwate</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tochigi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kumamoto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kyoto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Osaka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Daugavpils</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Riga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Ventspils</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Estado de Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Jalisco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Nuevo Leon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Aguascalientes, Ags</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Distrito Federal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Masovian</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Chelm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Kraksaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Osielsko</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Siedlce</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Skierniewice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroc¿aw</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>A Study to evaluate efficacy and safety in subjects with moderate to severe Psoriasis treated
      with BMS-986165</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02931838</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</name>
      <address />
      <phone />
      <fax />
      <email>Clinical.Trials@bms.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>